Multivariable evaluation of candidates for cardiovascular disease

Essential Cardiology: Principles and Practice: Second Edition

Volumn , Issue , 2006, Pages 3-18

  Kannel, William B ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861037046     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-918-9_1     Document Type: Chapter

References (45)

1. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992;326: 1406-1416.
2. Kannel WB. Contribution of the Framingham Study to preventive cardiology. J Am Coll Cardiol 1990;15:206-211.
3. Anderson KM, Wilson PWF, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation 1991;83:357-363.
4. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-318.
5. Murabito JM, D'Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication: a risk profile from the Framing-ham Study. Circulation 1997;96:44-49.
6. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med 1999; 159:1197-1204.
7. Kannel WB, Sytkowski PA. Atherosclerosis risk factors. Pharmacol Ther 1987;32:207-235.
8. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 1979;2:120-126.
9. Kannel WB, Wilson PWF. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995; 155:57-91.
10. NIH Consensus Development Panel. Triglyceride, high-density lipoprotein and coronary heart disease. JAMA 1993; 269:505-510.
11. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983;52:9B-12B.
12. Wilson PWF, Kannel WB. Hypercholesterolemia and coronary risk in the elderly: The Framingham Study. Am J Geriat Cardiol 1993;2:52-56.
13. Corti MC, Guralnic JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995;274:539-544.
14. Kannel WB, Dawber TR, McGee DL, et al. Perspectives on systolic blood hypertension: The Framingham Study. Circulation 1980;61:1179-1182.
15. Franklin SS, Kahn SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999;100:354-360.
16. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
17. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA 2001; 285: 2486-2497.
18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults. JAMA 2002;287: 356-259.
19. Castelli WP, Wilson PWF, Levy D, Anderson K. Cardiovascular risk factors in the elderly. Am J Cardiol 1989; 63:12H-19H.
20. Kannel WB. Epidemiologic relationship of disease among the different vascular territories. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease, vol. II. Lippincott-Raven, Philadelphia, 1996, pp. 1591-1599.
21. Cupples LA, Gagnon DR, Wong ND, et al. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction. The Framingham Study. Am Heart J 1993;125:863-872.
22. Koenig W. Haemostatic risk factors for cardiovascular disease. Eur Heart J 1998;19(Suppl C):C39-C43.
23. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease. N Engl J Med 1997;336:973-979.
24. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050.
25. Leaverton PE, Sorlie PD, Kleinman JC, et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis 1987;40:775-784.
26. Brand RJ, Rosenmann RH, Sholtz RI, et al. Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham Study. Circulation 1976;53:348-355.
27. Schulte H, Assmann G. CHD risk equations obtained from the Framingham Heart Study applied to PRO-CAM Study. Cardiovascular Risk Factors 1991;1:126-133.
28. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
29. Ho KL, Anderson KM, Grossman W, Levy D. Survival after onset of congestive heart failure in the Framingham Study. Circulation 1993;88:107-115.
30. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1994;121:951-957.
31. Califf RM, Armstrong PW, Carver JR, et al. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996;5:1007-1019.
32. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326:1406-1416.
33. Rich-Edwards JW, Manson JE, Hennekens CH, et al. The primary prevention of coronary heart disease in women. N Engl J Med 1995;332:1758-1766.
34. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
35. Downs JR, Clearfield M, Weis S, et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622.
36. Systolic Hypertension in the Elderly Program Cooperative Research Group. Prevention of stroke by antihyperten-sive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
37. Stassen JA, Fagard R, Thijs L, et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial investigators. Lancet 1997;350:757-764
38. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing group for the Women's Health Initiative investigators. JAMA 2002;288:321-333.
39. Hulley S, Grady D, Bush T, Furberg C, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. For the Heart and Estrogen Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
40. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen, cigarette smoking and cardiovascular disease. The Framingham Study. N Engl J Med 1985;313:1038-1043.
41. Kannel WB, Wilson PWF. Comparison of risk profiles for cardiovascular events: implications for prevention. In: Abboud FM, ed. Advances in Internal Medicine. Mosby Yearbook, Chicago, 1997, pp. 39-66.
42. Kannel WB, Wilson PWF. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992;124:768-774.
43. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000;85:251-255.
44. Kannel WB. Epidemiologic contributions to preventive cardiology and challenges for the 21st century. In: Wong, Black, Gardin, eds. Practical Strategies in Preventing Heart Disease. McGraw Hill, New York, 2000, pp. 3-20.
45. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease. Circulation 1998;97:1837.